Open an account Help & support Register Account summary Log out
Skip Header
Home Stock market news

Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Abbott Laboratories to buy Exact Sciences in $23bn deal

Thu 20 Nov 2025 14:14

(Sharecast News) - Abbott Laboratories said on Thursday that it has agreed to buy cancer diagnostics firm Exact Sciences for $23bn. Under the terms of the deal, which is expected to close in the second quarter of next year, Exact Sciences shareholders will receive $105 per share.

Exact Sciences focuses on the early detection of cancer and supporting personalised treatments. Abbott said the company's comprehensive product offerings support patients and their healthcare providers before, during and after a cancer diagnosis.

"The company is a leader in cancer screening, precision oncology and genetic testing, helping to detect cancer earlier, guide treatment decisions and monitor for recurrence," it said.

Abbott chairman and chief executive Robert B. Ford said: "Exact Sciences' innovation, its strong brand and customer-focused execution are unrivalled in the cancer diagnostics space, and its presence and strengths are complementary to our own.

"Abbott has repeatedly taken on the world's most challenging health issues and made a meaningful impact on the lives of people in areas such as diabetes, cardiovascular disease and infectious diseases. We're excited to bring Exact Sciences' people and know-how into Abbott so that together, we can take on the global challenge of cancer."

At 1535 GMT, Exact Sciences shares were up 17% at $101.39, while Abbott was down 2.5% at $123.01.

Share this article

Related Sharecast Articles

Wed 14 Oct 2026 12:08
Thursday preview: TSMC results, UK GDP in focus
(Sharecast News) - Thursday will see the release of a first-quarter trading update from homeware retailer Dunelm and UK GDP data.
Wed 14 Oct 2026 11:30
Jefferies upgrades Pennon to 'buy'
(Sharecast News) - Jefferies upgraded Pennon to 'buy' from 'hold' on Wednesday but cut the price target to 380p from 500p.
Wed 14 Oct 2026 10:11
Berenberg lowers target price on Oxford Instruments
(Sharecast News) - Analysts at Berenberg lowered their target price on Oxford Instruments to 2,840p from 3,000p, noting the recent strength in order intake now looks largely priced in.
Wed 14 Oct 2026 10:10
Great Portland Estates secures £19m of lettings
(Sharecast News) - Property development and investment firm Great Portland Estates said on Wednesday that it had secured £19m of lettings in the first half, with deals struck 4.1% ahead of enterprise rental value.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Awards

Award 1
Award 2
Award 3

Policies and important information

Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statements | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Statutory and Regulatory disclosures | Whistleblowing programme

Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document or Product Summary document which contains important information about the fund.

This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.

© FIL Limited 2026